TABLE 2

Islet cell function tests, insulin sensitivity, and disposition index

LiraglutidePlaceboP
Intravenous glucose tolerance test
 Insulin total AUC 9.15–9.32 h (pmol · l−1 · h)55.45 ± 9.9334.26 ± 6.40.008
 Maximal insulin concentration 9.15–9.32 h (pmol/l)262.6 ± 47.5166.5 ± 32.40.007
Hyperglycemic clamp, steady state
 Insulin concentration (pmol/l)929.6 ± 262.9271.9 ± 53.30.015
 Proinsulin/insulin ratio0.09 ± 0.020.18 ± 0.030.001
 Glucagon concentration (pg/ml)55.5 ± 3.766.7 ± 3.50.005
 GIR/average serum insulin (arbitrary units)0.13 ± 0.030.15 ± 0.040.392
Arginine stimulation test
 Insulin total AUC 11.15–11.45 h (pmol · l−1 · h)799.6 ± 190307.2 ± 65.50.004
 Maximal insulin concentration (pmol/l)2,539 ± 5231,518 ± 2960.005
 Glucagon total AUC 11.15–11.45 h (pg · l−1 · h)40.7 ± 2.548.7 ± 3.00.012
 Maximal glucagon concentration (pg/ml)162.0 ± 13.7193.4 ± 140.034
HOMA analysis
 β-Cell function (% of normal)59.95 ± 8.8446.07 ± 9.860.010
 Insulin resistance (fold normal)4.09 ± 0.844.74 ± 1.150.373
Disposition index (pmol/l*HOMA-R)80.4 ± 1441.9 ± 50.008
  • Data are means ± SEM. GIR, glucose infusion rate.